[Fate Therapeutics, Inc] Fate Therapeutics, Inc. announced that the CIRM has awarded the Company a $15.0 million grant to support the clinical development of RECLAIM-LN, the Company's Phase II, potentially registrational trial of FT819 off-the-shelf CAR T cell in patients with refractory moderate-to-severe Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN).

[Monash University] A new $1.5 million National Health and Medical Research Council Partnership Project grant has been awarded to a project addressing one of the most significant challenges facing CAR-T cell therapy - toxicity affecting the brain.

[Nature Medicine] Researchers identified profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal, and glial cell remodeling to be associated with CAR-T cell-induced enterocolitis.

[Critical Reviews in Oncology/Hematology] The authors critically evaluate the landscape of osteosarcoma T cell therapies strictly through the lens of preclinical model evolution.

[Cell Reports Medicine] Investigators reported that inhibition of H3K27 methyltransferase EZH2 and, to a much lesser degree, the DNA methyltransferase DNMT1 and the H3K9 methyltransferase G9A promotes ROR1 expression by malignant cells.

[Cell] Functional validation in human and murine CAR-T cell models demonstrated that valeric acid supplementation enhanced, while indole-3-carboxaldehyde and isovaleric acid impaired, CAR-T cell efficacy.

[Molecular Therapy - Nucleic Acids] Researchers described a CAR-restricted T cell expansion platform generating yields of CRISPRa-CAR T cells far exceeding those required for genome-scale screening.

[Cancer Immunology Research] Investigators employed CAR-T cells directed against CD176 for treatment of non-small cell lung cancer. CD176-CAR-T cells were optimized with an additional inducible cassette encoding IL-18 or IL-12 to augment antitumor reactivity through autocrine and paracrine signaling.

[Nature] China has become a hotspot for developing and trialling innovative therapies that could transform the treatment of cancer and autoimmune diseases.

[iScience] Scientists designed a TCR-regulatory T cells (Treg) that recognizes a dominant epitope of the Ro60 antigen presented by HLA-DRB1∗03:01 and demonstrate that these cells can selectively suppress autoreactive T cells more effectively than polyclonal Treg.

[Rubedo Life Sciences (BusinessWire)] Rubedo Life Sciences announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia, the most prevalent form of hair loss globally, beginning October 2026

[LEO Pharma] LEO Pharma announced that the US FDA has accepted for filing and granted Priority Review to the New Drug Application for dersimelagon, a potential first-in-class oral therapy for erythropoietic protoporphyria and X-linked protoporphyria, two rare genetic skin diseases.